The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Sorting Out the CRISPR Patent Case
Sounds of Science Podcast
For full access to this article login to GEN Select now.
Getting Around Downstream Bottlenecks
A Variety of Total and Incremental Solutions Exist for Firms Not Averse to Change
- Prevailing wisdom holds that upstream efficiencies cause downstream bottlenecks. Yet perceptions regarding bottlenecks, their sources, and how to deal with them differ widely. Downstream bottlenecks can occur at any step, particularly at innately slow steps like chromatography, or where pooling or hold-up are involved. Virus removal or inactivation, ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.